euro adhoc: Intercell AG / Joint Ventures/Cooperation/Collaboration / USD 12.5 m funding for the development of Intercell's vaccine patch system for Pandemic Influenza from U.S. Department of Health a

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

Research & Development

10.12.2008

Vienna/Austria, December 10, 2008 - Intercell AG (VSE: ICLL) today
announced the execution of a contract modification with the U.S.
Department of Health and Human Services (HHS). The agreement commits
additional funding of USD 12.5 m for Intercell's Pandemic Influenza
program.

Intercell is developing a Pandemic Influenza Vaccine Patch System
that includes an immunostimulant patch administered in conjunction
with an injected Pandemic Influenza vaccine (manufactured by Solvay
Biologicals, B.V., The Netherlands); the system is designed to
enhance the immune response and enable dose sparing of the Pandemic
Influenza vaccine.

The actual funding forms part of an HHS contract with potential
funding of up to USD 128 m over five years. If successful,
Intercell's Pandemic Influenza Vaccine Patch System would have the
effect of expanding limited vaccine supplies by allowing fewer or
lower doses of the vaccine.

The next Phase II study is expected to start in early 2009 and will
be a randomized, blinded study to determine the optimal combination
and dose of an injected H5N1 influenza vaccine and the vaccine patch
from Intercell. The study will be conducted in the U.S. and is
expected to enroll 500 subjects at six study sites.

The initial Phase I/II clinical trial funded under this HHS contract
demonstrated that a single 45-microgram dose of an injected H5N1
influenza vaccine, coupled with a single 50-microgram Intercell patch
was sufficient to provide an immune response considered protective in
73 percent of those tested: a statistically significant improvement
over those who received the H5N1 influenza vaccine alone. The trial
was one of the first to demonstrate that a single dose of Pandemic
Influenza vaccine may meet the level of protection suggested in U.S.
Food and Drug Administration (FDA) guidance.

Thomas Lingelbach, COO of Intercell AG and CEO of Intercell USA
commented: "The financial support from HHS enables us to continue our
Pandemic Flu program with full speed in 2009. The progress of this
program is also an important endorsement of the ability of our patch
technology to enhance the immune response, when combining it with an
injected vaccine."

About Pandemic Influenza Three influenza pandemics have occurred in
the 20th century leading to the death of more than 50 million people
globally. By U.S. government estimates, pandemic influenza has a
greater potential to cause deaths and illnesses than virtually any
other natural health threat. Signs of a pandemic influenza have
emerged in Southeast Asia, as lethal infections of poultry and humans
with avian influenza virus continue. The current virus is now endemic
in bird populations, having spread to more than 40 countries and
causing the deaths of hundreds of millions of birds. Furthermore, the
World Health Organization reports that the number of avian flu cases
in humans has reached more than 370 cases in 14 countries.

Development of Pandemic Influenza Vaccines Intercell believes that
its vaccine patch (immunostimulant patch) has the potential for the
development of improved influenza vaccines, especially in the field
of pandemic influenza. Preclinical studies and the Phase I/II
clinical study results using the patch with H5N1 vaccine suggest that
this strategy may be used for other applications where improved
immunogenicity, decreased antigen doses, or fewer immunization visits
are desired.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Head of Corporate Communications

Tel. +43 1 20620-1303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market